国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (3): 158-162.doi: 10.3760/cma.j.cn371439-20240830-00024

• 论著 • 上一篇    下一篇

iRhom1、iRhom2、TNF-α水平对宫颈癌患者预后的预测价值

韩涛, 贾沛沛, 鲁静()   

  1. 新疆维吾尔自治区人民医院妇科,乌鲁木齐 830001
  • 收稿日期:2024-08-30 修回日期:2024-11-19 出版日期:2025-03-08 发布日期:2025-04-02
  • 通讯作者: 鲁静,Email:497741940@qq.com

Predictive value of iRhom1,iRhom2 and TNF-α levels for the prognosis of patients with cervical cancer

Han Tao, Jia Peipei, Lu Jing()   

  1. Department of Gynecology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China
  • Received:2024-08-30 Revised:2024-11-19 Online:2025-03-08 Published:2025-04-02
  • Contact: Lu Jing,Email:497741940@qq.com

摘要:

目的 探究不同预后的宫颈癌患者非活化菱形蛋白(iRhom)1、iRhom2、肿瘤坏死因子α(TNF-α)水平差异, 分析各指标对患者预后的预测价值。方法 选择2021年6月至2023年6月于新疆维吾尔自治区人民医院行广泛性子宫切除术的90例宫颈癌患者作为研究对象。通过倾向性评分匹配的方法, 以0.02卡钳值筛选30例一般临床资料匹配的宫颈活检正常患者作为对照。根据患者预后情况, 将宫颈癌患者分为预后良好组(n=69)和预后不良组(n=21)。采用蛋白质印迹法检测组织样本中iRhom1、iRhom2、TNF-α的蛋白水平。比较宫颈癌组织、癌旁组织、正常宫颈组织以及预后良好组与预后不良组iRhom1、iRhom2和TNF-α蛋白水平差异。采用多因素logistic回归分析宫颈癌患者预后的影响因素, 采用受试者操作特征(ROC)曲线评价各指标对宫颈癌患者预后的预测效能。结果 宫颈癌组织、癌旁组织、正常宫颈组织中iRhom1蛋白水平分别为0.80±0.11、0.41±0.10、0.40±0.07, iRhom2分别为0.81±0.12、0.47±0.10、0.46±0.05, TNF-α分别为1.15±0.12、0.58±0.10、0.56±0.07, 3组间iRhom1、iRhom2、TNF-α蛋白水平差异均有统计学意义(F=64.93, P<0.001;F=56.14, P<0.001;F=191.61, P<0.001)。宫颈癌组织与癌旁组织、正常宫颈组织中iRhom1、iRhom2、TNF-α蛋白水平相比, 差异均有统计学意义(均P<0.05)。预后不良组、预后良好组宫颈癌组织中iRhom1蛋白水平分别为0.90±0.12、0.77±0.10, iRhom2分别为0.90±0.10、0.79±0.09, TNF-α分别为1.29±0.13、1.06±0.10, 两组间iRhom1、iRhom2、TNF-α蛋白水平差异均有统计学意义(t=7.31, P<0.001;t=5.35, P<0.001;t=10.30, P<0.001)。多因素logistic回归分析显示, iRhom1(OR=2.29, 95%CI为1.77~3.71, P<0.001)、iRhom2(OR=1.51, 95%CI为1.10~2.71, P<0.001)、TNF-α(OR=2.10, 95%CI为1.90~4.44, P<0.001)均是宫颈癌患者预后的独立影响因素。ROC曲线显示, iRhom1(AUC为0.88, 95%CI为0.80~0.97)、iRhom2(AUC为0.83, 95%CI为0.73~0.94)、TNF-α(AUC为0.80, 95%CI为0.65~0.94)单独及联合检测(AUC=0.97, 95%CI为0.93~1.00)均可预测宫颈癌患者预后。结论 宫颈癌组织中iRhom1、iRhom2、TNF-α蛋白水平均高于癌旁组织、正常宫颈组织, 且3项指标在预后不良宫颈癌组织中的水平均显著高于预后良好宫颈癌组织。iRhom1、iRhom2、TNF-α蛋白水平均是宫颈癌患者预后的独立影响因素, 3项指标单独或联合检测均可预测宫颈癌患者预后。

关键词: 宫颈肿瘤, 肿瘤坏死因子α, 预后, 非活化菱形蛋白

Abstract:

Objective To investigate the differences in the levels of inactive rhomboid protein (iRhom) 1, iRhom2, and tumor necrosis factor-α (TNF-α) in cervical cancer patients with different prognoses, and to analyze the predictive value of each index for patient's prognosis. Methods A total of 90 cervical cancer patients who underwent extensive hysterectomy at the People's Hospital of Xinjiang Uygur Autonomous Region from June 2021 to June 2023 were selected as the study objects. Using a propensity score matching method with a caliper value of 0.02, 30 cases with normal cervical biopsy results and matched general clinical data were selected as the controls. Cervical cancer patients were divided into the good prognosis group (n=69) and the poor prognosis group (n=21) according to the prognosis. Western blotting was used to detect the protein levels of iRhom1, iRhom2, and TNF-α in tissue samples. The differences in iRhom1, iRhom2, and TNF-α protein levels between cervical cancer tissues, adjacent tissues, normal cervical tissues, and between the good and poor prognosis groups were compared. Multivariate logistic regression was used to analyze the influencing factors of prognosis in cervical cancer patients, and the receiver operator characteristic (ROC) curve was used to evaluate the predictive efficacy of each indicator for prognosis in cervical cancer patients. Results The levels of iRhom1 protein in cervical cancer tissues, adjacent tissues, and normal cervical tissues were 0.80±0.11, 0.41±0.10, 0.40±0.07, respectively; those of iRhom2 were 0.81±0.12, 0.47±0.10, 0.46±0.05, respectively; and those of TNF-α were 1.15±0.12, 0.58±0.10, 0.56±0.07, respectively. There were statistically significant differences in the levels of iRhom1, iRhom2, and TNF-α protein among the three groups (F=64.93, P<0.001; F=56.14, P<0.001; F=191.61, P<0.001). There were statistically significant differences in the levels of iRhom1, iRhom2 and TNF-α between cervical cancer tissues and adjacent tissues and normal cervical tissues (all P<0.05). In the poor prognosis group and the good prognosis group, the levels of iRhom1 protein in cervical cancer tissues were 0.90±0.12 and 0.77±0.10, respectively; those of iRhom2 were 0.90±0.10 and 0.79±0.09, respectively; and those of TNF-α were 1.29±0.13 and 1.06±0.10, respectively. There were statistically significant differences in iRhom1, iRhom2, and TNF-α protein levels between the two groups (t=7.31, P<0.001; t=5.35, P<0.001; t=10.30, P<0.001). Multivariate logistic regression analysis showed that, iRhom1 (OR=2.29, 95%CI:1.77-3.71, P<0.001), iRhom2 (OR=1.51, 95%CI:1.10-2.71, P<0.001), and TNF-α (OR=2.10, 95%CI:1.90-4.44, P<0.001) were all independent influencing factors of the prognosis of cervical cancer patients. The ROC curve indicated that iRhom1 (AUC=0.88, 95%CI:0.80-0.97), iRhom2 (AUC=0.83, 95%CI:0.73-0.94), and TNF-α (AUC=0.80, 95%CI:0.65-0.94) alone and in combination (AUC=0.97, 95%CI:0.93-1.00) could predict prognosis of cervical cancer patients. Conclusions The levels of iRhom1, iRhom2 and TNF-α proteins in cervical cancer tissues are higher than those in adjacent tissues and normal cervical tissues, and the levels of these three indexes in cervical cancer tissues with poor prognosis are significantly higher than those in cervical cancer tissues with good prognosis. The levels of iRhom1, iRhom2 and TNF-α protein are all independent factors influencing the prognosis of cervical cancer patients, and the three indicators alone or in combination can predict the prognosis of cervical cancer patients.

Key words: Uterine cervical neoplasms, Tumor necrosis factor-alpha, Prognosis, Inactive rhomboid protein